|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-12-22
|
|
pubmed:abstractText |
The purpose of this study was to evaluate the tolerability and efficacy of irofulven, a DNA interacting acylfulvene analog, as first line therapy for patients with recurrent or metastatic gastric cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
pubmed-author:BealePP,
pubmed-author:BoyerMM,
pubmed-author:Cancer Therapeutics Research Group (CTRG),
pubmed-author:ChanA T CAT,
pubmed-author:ChungH CHC,
pubmed-author:ClarkeSS,
pubmed-author:EADESC HCHJr,
pubmed-author:HoRR,
pubmed-author:HouC HCH,
pubmed-author:JeungH CHC,
pubmed-author:LimRR,
pubmed-author:MAOY CYC,
pubmed-author:MaBB,
pubmed-author:MaoJ CJC,
pubmed-author:NgE K WEK,
pubmed-author:OngS Y KSY,
pubmed-author:RohJ KJK,
pubmed-author:SomPP,
pubmed-author:YepPP,
pubmed-author:ZeeBennyB
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
59
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
295-300
|
|
pubmed:meshHeading |
pubmed-meshheading:16783579-Adenocarcinoma,
pubmed-meshheading:16783579-Adult,
pubmed-meshheading:16783579-Aged,
pubmed-meshheading:16783579-Antineoplastic Agents, Alkylating,
pubmed-meshheading:16783579-Female,
pubmed-meshheading:16783579-Humans,
pubmed-meshheading:16783579-Infusions, Intravenous,
pubmed-meshheading:16783579-Lymph Nodes,
pubmed-meshheading:16783579-Male,
pubmed-meshheading:16783579-Middle Aged,
pubmed-meshheading:16783579-Neoplasm Recurrence, Local,
pubmed-meshheading:16783579-Sesquiterpenes,
pubmed-meshheading:16783579-Stomach Neoplasms,
pubmed-meshheading:16783579-Survival Rate,
pubmed-meshheading:16783579-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).
|
|
pubmed:affiliation |
Comprehensive Cancer Trials Unit, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. winnieyeo@cuhk.edu.hk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
